Introduction
============

For a long time, hydrogen sulfide (H~2~S) was considered to be a colorless, flammable, water-soluble, and highly toxic environmental hazard with the characteristic smell of rotten eggs. However, research conducted over the last decade suggests that this gaseous molecule can be endogenously generated and exerts very important roles in organisms ([@B91], [@B92]; [@B115]; [@B64]). In mammals, endogenous H~2~S is mainly produced through the metabolism of [L]{.smallcaps}-cysteine and homocysteine by the catalysis of two pyridoxal-5′-phosphate (PLP)-dependent enzymes, cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) ([@B16]; [@B87]). It can also be generated from the PLP-independent 3-mercaptopyruvate sulfurtransferase (3-MST), or cysteine aminotransferase (CAT) in the presence of α-ketoglutarate. The optimum pH value of 3-MST and CAT for the catalytic H~2~S production is about 9.7, while the physiological pH value of human blood ranges from 7.35 to 7.45. Additionally, 3-mercaptopyruvate, a substrate of 3-MST, is quite unstable. Therefore, the biological significance of this enzymatic reaction remains controversial, especially under physiological conditions ([@B70]; [@B125]).

These H~2~S-producing enzymes are distributed throughout the body in a tissue-specific manner. In murine liver and kidney tissues, CBS and CSE are both expressed, but the protein level of CSE is significantly higher than that of CBS. At high substrate concentrations (up to 20 mM cysteine or homocysteine) the capacity for liver H~2~S production is approximately equal for CBS and CSE, whereas in the kidney CBS constitutes the major source of H~2~S ([@B46]). A number of studies have revealed that H~2~S can exert a variety of biological effects. For example, H~2~S is able to reduce vascular tone and stimulate angiogenesis ([@B56]; [@B78]). The genetic deletion of CSE in mice decreased H~2~S generation and led to pronounced hypertension and impaired endothelium-dependent vasorelaxation ([@B130]). In inflammatory response, H~2~S seems to be a double-edged sword. It can reduce inflammation and promote tissue repair by targeting many elements of the inflammatory cascade ([@B108]) whereas in endotoxic shock, H~2~S can trigger or facilitate inflammation response in the lungs ([@B58]). All of these findings suggest that the regulation of H~2~S content in the body may have great therapeutic value.

To understand the functions of H~2~S and develop H~2~S-related therapy, reagents that can be used to produce H~2~S *in vitro* and *in vivo* are often needed. Those compounds are known as H~2~S donors or stimulating reagents. The development of such chemicals has received much attention from medicinal chemists and chemical biologists. A number of different H~2~S donors have been reported and the topic of H~2~S donors have been reviewed several times ([@B59]; [@B143]; [@B89]; [@B144]; [@B148]). Herein, we provide an overview on current understanding of commonly used H~2~S donors and stimulating reagents. We focus our discussion on recent development of H~2~S donors, donor materials, and stimulating reagents. It is worthwhile to note that cancer and glycometabolic disorders have become an increasing public health concern throughout the world. Recent studies have revealed some unique functions of H~2~S in these diseases. Therefore, in this article we also reviewed the studies and results of applying H~2~S in these pathophysiological processes.

Donors of Hydrogen Sulfide
==========================

Gaseous H~2~S
-------------

H~2~S gas can be inhaled by testing animals. Therefore, experiment animals can be put into an H~2~S-riched environment to observe H~2~S's physiological effects or toxicity. For example, it was found that when mice were exposed to 80 ppm of H~2~S for 6 h, their oxygen consumption dropped by ∼50%, and the metabolic rate and core body temperature were also significantly decreased into a suspended animation state ([@B8]). This effect is associated with the inhibition of cytochrome C oxidase of the electron transport chain during oxidative phosphorylation ([@B4]). Notably, lowering metabolic demand could be useful for the reduction of physiological damage caused by trauma and improve outcomes after surgery ([@B8]). However, a later study of various larger species, such as sheep, swine, and human, indicated that H~2~S only exerted thermoregulatory effects ([@B107]). H~2~S has good solubility in water (110 mM/atm at room temperature; 210 mM/atm at 0°C). Therefore, solutions of H~2~S gas are often used in studies. For example, in type 2 diabetes H~2~S gas solutions were used and it was found that they could promote glucose uptake through amelioration of insulin resistance and reduce renal injury ([@B124]). It should be noted that solutions with precise H~2~S concentrations are difficult to obtain, as H~2~S gas can easily escape from the solutions leading to a decreased concentration. In addition, H~2~S is a highly toxic gas, especially at high concentrations. These problems limit the use of H~2~S gas as a suitable reagent for many researchers.

Inorganic Sulfide Salts
-----------------------

Under physiological pH, H~2~S is in fast equilibrium with HS^-^ in aqueous solutions. The proportions of HS^-^ and H~2~S are 81 and 19%, respectively. Therefore, inorganic sulfide salts, such as sodium hydrosulfide (NaHS) and sodium sulfide (Na~2~S), are often used as H~2~S equivalents in many studies. These salts are easy to obtain and widely used in the preparation of H~2~S solutions. However, these salts are considered to be fast H~2~S donors, as they produce H~2~S immediately when dissolved in aqueous solutions. Moreover, H~2~S molecule can rapidly escape from the buffers under a variety of experimental conditions, such as in the studies of tissue culture plates, muscle myograph baths, and Langendorff perfused heart apparatus ([@B23]). This loss of H~2~S is mainly due to the rapid volatilization of H~2~S. This problem may explain the discrepancy between low H~2~S concentrations in blood and tissues versus high concentrations of exogenous H~2~S (when sulfide salts are used) required to produce physiological responses ([@B23]). When exposed to high concentrations of H~2~S for a short period of time, tissues and cells may be damaged or show different responses, therefore, it is hard to investigate the effects of physiological concentrations of H~2~S (at low μM or nM levels). Another problem is that H~2~S tends to oxidize, particularly in the presence of metal contaminants in solutions. It is therefore recommended to prepare solutions in anaerobic water/buffers. The addition of heavy metal chelators, like DTPA (diethylenetriaminepentaacetic acid), can chelate metal ions and stabilize H~2~S in solutions. The use of DTPA is highly recommended when working with H~2~S solutions.

Nevertheless, NaHS has been used as a standard H~2~S donor in many studies. For example, it was demonstrated that NaHS could alleviate amyloid beta-peptide (Aβ) ~25-35~-induced neural lesion in an Alzheimer's disease cellular model ([@B96]). In doxorubicin-induced cardiotoxicity, NaHS was found to reduce cardiomyocyte injury through inhibition of endoplasmic reticulum (ER) stress ([@B116]). In hypoxic skin damage, NaHS could exert anti-inflammatory effects through inhibition of reactive oxygen species (ROS)-activated nuclear factor kappa B (NF-κB)/cyclooxygenase (COX)-2 ([@B126]). Meanwhile, some researchers prefer using Na~2~S as the H~2~S donor. For example, Lefer and colleagues suggested that Na~2~S could attenuate mouse myocardial ischemia-reperfusion injury by preservation of mitochondrial function ([@B27]). In another study on inflammatory modulation, the administration of Na~2~S (28 μmol/kg) was proved to suppress carrageenan-induced rat paw edema by producing H~2~S ([@B136]). Notably, the intravenous administration of Na~2~S (0.005--0.20 mg/kg, infused over 1 min) to healthy human volunteers increased blood sulfide and thiosulfate concentrations, as well as exhaled H~2~S gas ([@B101]). Clinically, the elevated amount of exhaled H~2~S gas by patients was used to predict a non-eosinophilic phenotype of chronic obstructive pulmonary disease ([@B140]) and the airway inflammation of asthma ([@B139]).

Garlic-Derived Sulfur-Containing Compounds
------------------------------------------

Garlic is rich in sulfur-containing compounds and can be considered as an active "H~2~S" pool. Allicin (diallyl thiosulfinate) is the most well-characterized compound in garlic. In aqueous solutions allicin decomposes to a number of reactive sulfur-containing compounds, including diallyl sulfide (DAS), diallyl disulfide (DADS), and diallyl trisulfide (DATS) ([@B2]), which can release H~2~S in different manners. DATS reacts rapidly with GSH to release H~2~S through thiol-disulfide exchange followed by allyl perthiol reduction by GSH. However, DADS only releases a minute amount of H~2~S via a sluggish reaction with GSH through an alpha-carbon nucleophilic substitution pathway ([@B60]). In human erythrocytes, garlic-derived organic polysulfides could be converted into H~2~S through formation of a key intermediate, hydropolysulfide (RS~n~H) ([@B6]). In recent years, DADS and DATS have often been used as H~2~S donors to investigate their biologic actions. For example, it was shown that DADS can inhibit tumor cell proliferation and improve tissue repair ([@B20]). Since this class of H~2~S donors have been used clinically, the donation of H~2~S from them may have vital clinical significance.

Synthetic Slow-Releasing H~2~S Donors
-------------------------------------

Given the problems encountered with using H~2~S gas or sulfide salts in studies, researchers have explored a number of synthetic small molecules as H~2~S-releasing agents, e.g., H~2~S donors. These compounds are usually stable in physiological buffers. When applied to biological systems, they can release H~2~S under different mechanisms, such as hydrolysis, photolysis, or via the interaction with biomolecules like biothiols or enzymes. Some representative synthetic H~2~S donors are shown in **Figure [1](#F1){ref-type="fig"}**. GYY4137, a Lawesson's reagent derivative, is perhaps the most well-known H~2~S donor. It has been used by many researchers as the standard slow H~2~S production source. The release of H~2~S from GYY4137 is very slow in aqueous solutions as well as after intravenous or intraperitoneal administration in animals ([@B59]; [@B15]). GYY4137's H~2~S release mechanism is suggested to be due to direct hydrolysis or interacting with un-identified biomolecules but the details still need to be elucidated. A sulfur-containing heterocycle dithiolethione is another often-used H~2~S-releasing motif. It has been used particularly in the construction of hybrid drugs with non-steroidal anti-inflammatory drugs (NSAIDs). H~2~S-releasing NSAIDs are designed with the primary goal of using H~2~S to overcome gastric side-effects of traditional NSAIDs through improvement of blood flow, attenuation of oxidation and inflammation ([@B62]). A series of H~2~S-releasing NSAIDs have been developed, such as HS-aspirin (ACS14) (**Figure [1](#F1){ref-type="fig"}**), HS-sulindac, HS-ibuprofen, HS-naproxen, S-sulindac, S-ibuprofen, and S-naproxen, and their inhibitory effects on cancer cells have also been described in detail ([@B13]; [@B53]; [@B106]; [@B22]). Besides the gastric protection and the effects against cancer, these hybrids have shown more potentials for relieving inflammatory pain than the traditional NSAIDs ([@B32]). However, to date, it is still unclear how H~2~S is generated from dithiolethiones nor is the by-product known. Therefore, this lack of information may be a problem in developing these compounds for clinic uses.

![The structures of representative synthetic H~2~S donors.](fphar-08-00664-g001){#F1}

H~2~S release from the aforementioned donors is considered non-controllable, as the release is either due to the donor's spontaneous hydrolysis or the mechanism is still unknown. Recently, some controllable H~2~S donors have been developed. The representative examples are persulfide-based donors ([@B142]), *N*-mercapto-based donors ([@B145]), and JK type donors ([@B49]; [@B127]), which are also shown in **Figure [1](#F1){ref-type="fig"}**. These are considered "controllable" donors because their H~2~S release mechanisms are clearly exploited and the structural modifications could lead to H~2~S release profile changes (faster or slower). As such, these compounds can potentially be used for precisely delivering H~2~S in biological systems. Nevertheless these synthetic donors have been reviewed multiple times. Interested readers can refer to those review articles ([@B143]; [@B147]). Herein we would like to focus on some recent developments in this field.

Ammonium Tetrathiomolybdate
---------------------------

Thiomolybdate salts have been used as thiol transfer reagents in organic synthesis ([@B81]). The four sulfur atoms in the structures also make them excellent copper chelators. Ammonium tetrathiomolybdate (TTM) (**Figure [2](#F2){ref-type="fig"}**) has been used clinically as a treatment for copper toxicity, especially for Wilson's disease ([@B9]), a genetically recessive disease of copper accumulation. TTM's pharmacology and toxicology have been thoroughly studied ([@B10]). Also, it is known that TTM can produce H~2~S under strong acidic conditions such as 5% H~2~SO~4~ ([@B111]). As such, it is possible to repurpose TTM as a unique inorganic complex-based H~2~S donor, analogous to the discovery of sodium nitroprusside as a widely used nitric oxide (NO) donor ([@B41]). To this end, we studied TTM's H~2~S-generation and relevant activities under physiological conditions ([@B122]). Using a modified methylene blue method, commercially purchased TTM (99.97% purity from Sigma-Aldrich) was used to test H~2~S release in phosphate-buffered saline under pH 5, 6, 7.4, and 8. The results showed that TTM released H~2~S upon solvation, and H~2~S concentrations in all pH levels were maintained at a steady level for up to 15 h. These results suggest that TTM is a slow H~2~S releaser, similar to GYY4137. It was also found that acidic pH could accelerate TTM's H~2~S release. Further studies in cellular models showed TTM could protect cells under oxidative stress (treated by H~2~O~2~). These preliminary results indicate TTM is a promising H~2~S donor ([@B122]). A recent study has shown that TTM could attenuate myocardial and cerebral injury induced by ischemia/reperfusion ([@B26]). More studies on it are expected to come in the next years.

![The chemical structure of TTM.](fphar-08-00664-g002){#F2}

Reactive Oxygen Species Activated H~2~S Donors
----------------------------------------------

In 2016, Pluth and colleague designed several interesting ROS activated H~2~S donors ([@B144]). These caged thiocarbamate compounds bear a pinacol boron functional group, which can be oxidized and cleaved to hydroxyl (-OH) by ROS, like hydrogen peroxide (H~2~O~2~). A tandem reaction will then occur and release carbonyl sulfide (COS), as well as quinone and amine byproducts (**Figure [3](#F3){ref-type="fig"}**). It is worth noting that COS can easily undergo hydrolysis to produce H~2~S if carbonic anhydrase (CA) is presented ([@B89]). This work represents the first ROS triggered H~2~S donors. It was found that the reaction rates could be tuned by electronic modulation of thiocarbamates. Interestingly, further studies showed CA is not required for the donors' H~2~S release as H~2~O~2~ can also trigger the rapid transformation of COS to H~2~S. Cellular imaging experiments demonstrated the donors, such as Peroxy TCM, can release H~2~S with activation of both exogenous H~2~O~2~ and endogenous H~2~O~2~ in cells. The donors can increase cell viability under H~2~O~2~-induced oxidative stress, while the control compounds without aryl boron moiety, which produces H~2~O instead of H~2~S, show little or no protective effects against H~2~O~2~ induced damage. These results indicate that these donors are effective under ROS stimulation.

![H~2~O~2~-mediated COS/H~2~S release from Peroxy TCM donors.](fphar-08-00664-g003){#F3}

Enzyme Activated H~2~S Donors
-----------------------------

Also in 2016, Wang and colleagues reported a series of esterase activated H~2~S donors (**Figure [4](#F4){ref-type="fig"}**) ([@B148]). These donors contain a thioacid moiety and an ester-masked nucleophilic phenol in a "trimethyl lock" template. After the ester group is removed by an esterase, a spontaneous intramolecular lactonization occurs, resulting in the release of H~2~S. Experimental data showed the donors require porcine liver esterase or cell culture media containing FBS to release H~2~S, confirming the donors' selectivity and chemical stability. Additionally, their H~2~S-releasing rates can be tuned by adjusting ester substituents and the trimethyl lock structure. In RAW 264.7 cells, these donors inhibited lipopolysaccharide-induced tumor necrosis factor (TNF)-α secretion, suggesting the H~2~S-related anti-inflammatory effects, while control compounds without the H~2~S-releasing moiety did not show such effects. These esterase activated donors can be conjugated to NSAIDs to form H~2~S--NSAID hybrids. Such hybrids, like HP-105, could utilize H~2~S's anti-inflammatory and anti-oxidative effects to ameliorate NSAIDs-induced gastric damage. However, detailed biological evaluations of these new H~2~S--NSAID hybrids have yet to be seen.

![H~2~S release from esterase-activated donors.](fphar-08-00664-g004){#F4}

Besides Wang's work ([@B148]), Chakrapani and colleagues also designed esterase-activated H~2~S donors (**Figure [5](#F5){ref-type="fig"}**), utilizing carbamothioates and carbonothioates to generate COS as the H~2~S precursor ([@B14]). COS is then hydrolyzed by CA to produce H~2~S. These donors' ability of generating H~2~S when esterase and CA are both presented has been proven by various studies ([@B88],[@B90]). Kinetics studies showed the decomposition of the compounds may go through a short-lived intermediate.

![Esterase-activated COS/H~2~S release.](fphar-08-00664-g005){#F5}

Nitroreductase (NTR)-activated H~2~S donors were recently reported by Chakrapani and colleagues ([@B86]). The donors contain 4-nitroaryl masking groups, which are good substrates for NTR. Upon nitro reduction, a *gem*-dithiol will be produced, and further converted to H~2~S (**Figure [6](#F6){ref-type="fig"}**). Fluorescent and monobromobimane assays proved the donors' H~2~S generation in cell-free conditions in the presence of bacterial NTR. The donors also generate H~2~S in bacterial cells that express NTR, but fail to generate H~2~S in bacterial cells or mammalian cells deficient in NTR. These donors were used as chemical tools to study H~2~S's role in antimicrobial resistance.

![Nitroreductase-activated H~2~S donors.](fphar-08-00664-g006){#F6}

These ROS- and enzyme-activated donors utilize interesting chemistry, and make their H~2~S release more controllable. They can be useful chemical tools. However, there are very few studies about their biological applications or therapeutic potentials. We look forward to these studies in the near future.

H~2~S-Releasing Materials
-------------------------

Compared to small molecule drugs, material-based drugs have some unique advantages, such as improved water solubility and stability, slower clearance rates, and reduced toxicity. Material-based drug delivery has been extensively studied. However, H~2~S-releasing biomaterials are relatively new in this field. In the past several years, a few such materials have been developed, which are summarized below.

In 2014, Matson and colleague prepared *S*-aroylthiooxime (SATO)-based polymers A (**Figure [7](#F7){ref-type="fig"}**) by functionalizing aldehyde-containing polymers with *S*-aroylthiohydroxylamines ([@B33]). In the presence of biological thiols, such as cysteine or GSH, the SATO moiety on the polymer can degrade to release H~2~S. The kinetics can be controlled by tuning electronics on SATO substituents. Recently, the same strategy was also employed to prepare SATO-based micelles by the same group ([@B34]). In this case, SATO was formed on polymer amphiphiles to give B, which undergoes self-assembly in THF-water solutions and forms micelles. Similarly, these micelles release H~2~S upon activation by biothiols. The micelles showed slower but more sustained H~2~S release than A and small molecule SATOs. This could be attributed to the more difficult diffusion of biothiols to the hydrophobic cores of micelles. In the presence of cysteine, the H~2~S-micelles showed cytotoxicity toward cancer cells, such as HCT 116 cells, but much reduced toxicity for "normal" cells such as NIH/3T3 cells, suggesting that H~2~S-micelles can selectively target cancer cells.

![**(A)** SATO based polymers. **(B)** SATO based micelles.](fphar-08-00664-g007){#F7}

In 2016, Matson's group developed polyNTA (**Figure [8](#F8){ref-type="fig"}**), a random polymer that can release H~2~S via the COS intermediate ([@B80]). This polymer contains *N*-thiocarboxyanhydrides (NTAs), which undergoes a ring-opening reaction with biological nucleophiles, such as amines to release COS. Then COS can be hydrolyzed to produce H~2~S in the presence of CA. PolyNTA was shown to generate H~2~S in buffers when glycine and CA were present. However, it failed to promote endothelial cell proliferation like small molecule H~2~S donors.

![The structures of polyNTA and PEG-ADT.](fphar-08-00664-g008){#F8}

Another example of an H~2~S-relasing polymer is PEG-ADT (**Figure [8](#F8){ref-type="fig"}**) developed by van der Vlies and colleague ([@B38]). In this work, H~2~S donor 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADT-OH) was conjugated to polyethylene glycol (PEG). PEG-ADT showed lower H~2~S generating capacity than its parent compound ADT-OH and reduced cytotoxicity. Cell imaging studies suggested PEG-ADT could enter cells via endocytosis and remain in the endolysosome, whereas ADT-OH enters the cytoplasm via membrane diffusion. This difference may lead to reduced toxicity of PEG-ADT.

Apart from chemical conjugations, Wang et al. ([@B29]; [@B120]) reported H~2~S-releasing nanofibers by physically adding H~2~S donor molecules to polycaprolactone (PCL) solutions and fabricated the materials with electrospinning. Two H~2~S-releasing nanofibers, thiol-activated H~2~S-fibers ([@B29]) and pH-activated PCL-JK1 ([@B120]) were prepared. These fibers showed prolonged H~2~S release compared to their parent small molecules. Notably, they also showed significant cytoprotection and improved wound healing capacity.

SG-1002
-------

SG-1002 (**Figure [9](#F9){ref-type="fig"}**) is an inorganic mixture, containing S~8~, Na~2~SO~4~, Na~2~S~2~O~3~, Na~2~S~3~O~6~, Na~2~S~4~O~6~, and Na~2~S~5~O~6~. It was developed by SulfaGENIX as an oral H~2~S donor for the treatment of heart diseases, like myocardial I/R injury and heart failure. In a pre-clinic study, SG-1002 effectively restored H~2~S and sulfane sulfur levels in mice with heart failure triggered by transverse aortic constriction (TAC) ([@B54]). SG-1002 treated mice suffered less cardiac enlargement and left ventricular (LV) dilation, and showed reduced fibrosis compared with mice fed by a control diet after TAC. Additionally, the treatment with SG-1002 upregulated the vascular endothelial growth factor (VEGF), protein kinase B (Akt), endothelial NO synthase, NO and cGMP pathway, and attenuated mitochondrial respiratory dysfunction and oxidative stress induced by TAC.

![SG-1002 Components.](fphar-08-00664-g009){#F9}

In another model study, SG-1002 attenuated cardiac dysfunction induced by a high fat diet (HFD) in mice ([@B3]). HFD fed mice showed decreased sulfide levels, metabolic perturbation such as increased serum glucose level and glucose intolerance, as well as cardiac dysfunction such as decreased LV function fraction and increased circumferential stress. Morphological histological analysis showed cardiac enlargement and fibrosis in HFD fed mice. However, the treatment with SG-1002 markedly ameliorated some of the metabolic perturbations and attenuated cardiac dysfunction. Further study showed that the treatment could restore adiponectin levels and suppress cardiac ER stress.

In a Phase I clinical trial ([@B79]), the effects of SG-1002 were tested on both healthy subjects and subjects with heart failure with dosages up to 800 mg twice daily for 7 days. Both groups showed increased H~2~S levels with only minor adverse effects observed. In addition, a double blind, placebo controlled Phase I trial (ClinicalTrials.gov Identifier: NCT01989208) is in process.

Despite the promise, no present study has described the H~2~S releasing mechanism of SG-1002 *in vivo*. We look forward to studies that elucidate the mechanism, which should provide new insight in H~2~S-related therapies.

H~2~S-Stimulating Agents
------------------------

In addition to donors that directly degrade to produce H~2~S via different chemical mechanisms, some compounds are known to stimulate H~2~S production *in vivo*. For example, [L]{.smallcaps}-cysteine is an important natural substrate of H~2~S-producing enzymes. When the amino group of [L]{.smallcaps}-cysteine is acetylated, the resulted product *N*-acetyl-[L]{.smallcaps}-cysteine (NAC) is one of the essential medicines listed by the World Health Organization (WHO). Although NAC has been used clinically as an expectorant ([@B85]) or an antioxidant in hepatic failure ([@B83]), no clinical trial has used it as a H~2~S donor. However, NAC was found to suppress leukocyte infiltration in an air pouch model through generation of endogenous H~2~S ([@B136]).

*S*-allyl-[L]{.smallcaps}-cysteine (SAC) ([@B51]) and *S*-propargyl-[L]{.smallcaps}-cysteine (SPRC) ([@B37]) (**Figure [10](#F10){ref-type="fig"}**) are two other cysteine derivatives that can be used as CSE substrates to produce H~2~S. The classical effects of H~2~S including antioxidation and cardioprotection were demonstrated in SAC treated rats suffering from isoproterenol toxicity ([@B75]). Zhu and colleagues further found that SAC's cardioprotective effects were associated with induction of CSE expression and enhancement of H~2~S generation ([@B19]). A recent study showed that SAC could suppress hepatocyte growth factor-induced migration and invasion in nasopharyngeal cancer cells ([@B17]). SAC could also exert anti-diabetic effects by means of improving beta-cell function and reducing glycemia ([@B50]).

![The Structures of SAC and SPRC and their H~2~S release reaction.](fphar-08-00664-g010){#F10}

SPRC is a structural analog of SAC and has expected similar effects as SAC, such as enhanced CSE expression and plasma H~2~S concentrations, as well as cardioprotection ([@B114]) and anti-cancer effects ([@B65]). Recently, it was documented that SPRC could prevent doxorubicin-induced cardiotoxicity ([@B119]), which is similar to the effects of NaHS used in previous studies ([@B116]). In addition, SPRC exhibited anti-inflammation ([@B112]), anti-apoptosis and anti-oxidation in high glucose treated cardiomyocytes ([@B132]).

Vitamin D (VD), a key endogenous hormone, has been thought to regulate calcium and phosphate metabolism contributing to bone growth and remodeling for a long time. In recent years, the extraskeletal effects of VD have been documented, such as cancer progression, cardiovascular action, and immune regulation ([@B18]). In fact, H~2~S can exert some coincident effects in the body with VD. Notably, [@B118] found that cholecalciferol, also known as VD~3~, could increase tissue H~2~S concentration in mouse heart, brain and kidney. Meanwhile, another report suggested that VD~3~ had ability to upregulate glucose transporter type 4 (GLUT4) and decreased glycemia in diabetes through induction of CSE expression and H~2~S generation ([@B69]). Moreover, in high glucose and methylglyoxal (MGO)-induced diabetic peripheral neuropathy, VD could exert significant protective roles through restoration of CBS expression and endogenous H~2~S formation ([@B138]).

**Table [1](#T1){ref-type="table"}** provides a brief summary of H~2~S donors and stimulating reagents covered in this review.

###### 

Summary of H~2~S releasing/stimulating reagents.

  Reagents                                                  Potential applications                                                                                Advantages                                                                   Disadvantages
  --------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Gaseous H~2~S                                             Reduce body temperature and metabolic rate; improve glucose uptake in type 2 diabetes                 Clean H~2~S source; no byproducts; easy administration; good absorbability   High volatility; difficult to control concentrations; uncontrolled H~2~S release
  **Inorganic sulfide salts**                                                                                                                                                                                                                  
  NaHS, Na~2~S                                              Widely used in cellular and animal disease models; intravenous administration to healthy volunteers   Good solubility; easy to handle; clean H~2~S source, no byproducts           High volatility; difficult to control concentrations; Uncontrolled H~2~S release
  **Garlic-derived sulfur containing compounds**                                                                                                                                                                                               
  DAS, DADS, DATS                                           Proliferative inhibition in tumor cells; improvement of tissue repair and myocardial function         Extensive data on a variety of models                                        Stability of polysulfides is a concern; interfere with GSH
  **Synthetic slow-releasing H~2~S donors**                                                                                                                                                                                                    
  GYY4137, ACS14                                            Cytoprotection; anti-cancer and anti-inflammation activities                                          Good stability; slow H~2~S release; ACS14 overcomes side effects of NSAIDs   Uncontrolled release; unclear release mechanism; produce byproducts
  **Novel controllable H~2~S donors**                                                                                                                                                                                                          
  *N*-mercapto/persulfide-based donors, JK donors           Myocardial/gastric preservation                                                                       Good stability; controlled H~2~S release                                     Produce byproducts
  Tetrathiomolybdate                                        A common Cu^2+^ chelator; dermal, myocardial and cerebral preservation                                Good stability and safety; a clinically used drug                            Unclear byproducts could cause side effects
  ROS-/enzyme-activated H~2~S donors                        Cytoprotection and anti-inflammation                                                                  Good stability; controlled H~2~S release                                     Produce byproducts; lacking *in vivo* data
  **H~2~S-releasing materials**                                                                                                                                                                                                                
  SATO-based polymers/micelles, polyNTA, PEG-ADT, PCL-JK1   Anti-cancer activity; improvement of wound healing; cardioprotection                                  Good solubility, stability, membrane permeability; slow clearance rates      More *in vivo* data are needed
  **H~2~S-stimulating agents**                                                                                                                                                                                                                 
  [L]{.smallcaps}-cysteine derivatives, Vitamin D           Anti-cancer, anti-diabetes, anti-oxidation, anti-inflammation, and cardioprotection                   Transformed into endogenous substances                                       

From the above sections, we can see that numerous H~2~S releasing/stimulating reagents have been developed so far and many of them have been used in cell- or animal-based disease models. However, very few of them have been further advanced into pre-clinic studies, indicating the development of H~2~S as therapeutics is still at the early stage. Nevertheless these studies have revealed interesting sulfur-related biological mechanisms, which can potentially impact future research in this area. In the following section, we intend to review the applications of H~2~S releasing/stimulating reagents in the studies of cancer and glycometabolic disorders, two very common health concerns in the world.

Hydrogen Sulfide and Cancer
===========================

Effects of H~2~S on Cell Cycle and Proliferation
------------------------------------------------

The cell cycle represents a series of tightly integrated events, which regulate the transition from cellular quiescence to proliferation, and thus ensure high fidelity of the genetic transcript ([@B84]). In eukaryotic cells, the cell cycle includes four conventional phases, i.e., Gap phase 1 (G1); DNA synthesis phase (S); Gap phase 2 (G2), during which the cell prepares itself for division, and mitosis phase (M), during which the chromosomes separate and the cell divides. Dysregulation of the cell cycle is an important cause of cellular overproliferation and cancer ([@B84]; [@B67]).

The treatment of oral squamous cell carcinoma cells, Cal27, GNM, and WSU-HN6, with a H~2~S donor, NaHS, significantly downregulated cell cycle regulatory genes, RPA70 and RB1, and upregulated proliferating cell nuclear antigen and cyclin-dependent kinase 4 (CDK4), resulting in cell proliferation ([@B66]). In human colon cancer HCT 116 cells and hepatocellular carcinoma cells, H~2~S-mediated proliferation was investigated through addition of NaHS and induction of CSE expression, respectively. It was found that the effects of H~2~S on tumorigenesis were associated with the decreased proportion of cells in G0--G1 phase, downregulation of cyclin-dependent kinase inhibitor p21, and with the increase in proportion of S phase cells ([@B11]; [@B134]). A recent study showed that by inhibiting endogenous CBS/H~2~S pathway quinolone-indolone conjugate (QIC)2 could significantly attenuate hepatoma cell proliferation ([@B43]). These findings suggest that H~2~S participates in the development of cancer through shortening cell cycle and inducing proliferation.

On the other hand, some researchers used SPRC as a H~2~S stimulating reagent, and found that the treatment with SPRC could induce cell cycle arrest at G1/S phase and consequently inhibit proliferation of SGC-7901 gastric cancer cells ([@B65]). The synthetic slow-releasing H~2~S donor, GYY4137, also showed similar anti-proliferation in hepatocellular carcinoma model ([@B63]). In addition, the exposure to GYY4137 for 8 days can induce cell cycle arrest at the G2/M phase in human breast adenocarcinoma MCF-7 cells ([@B55]). Some studies introduced H~2~S-releasing moieties to NSAIDs and found that these hybrids have enhanced anti-tumor activity and gastrointestinal (GI) safety compared with the prodrugs ([@B52],[@B53]). Of note, a study indicated that H~2~S-releasing NSAIDs inhibited cellular proliferation in a tissue type-independent manner ([@B13]). TTM also exerts anti-cancer effects through chelating and reducing copper, which can promote angiogenesis and feed an expanding tumor ([@B4]; [@B36]). However, it is still unclear if H~2~S is involved in TTM's anti-cancer effects.

From these studies, it has been indicated that H~2~S has both pro-proliferation and anti-proliferation, even in the same tumor cells, which seems to be conflicting. Notably, in the reports of H~2~S's pro-proliferation, the inorganic sulfide salts, such as NaHS and Na~2~S, were usually used. However, in the reports of H~2~S's anti-proliferation, the slow-releasing H~2~S donors such as GYY4137 and dithiolethione were used. Besides the different H~2~S release profiles, the former donors (e.g., NaHS and Na~2~S) are simple donors, whose byproduct can almost be neglected. However, the latter synthetic donors are structurally complicated and may produce biologically active byproducts after H~2~S release, or the donor molecules themselves can have H~2~S independent activities. Further studies are needed to clarify these effects.

Effects of H~2~S on Cellular Apoptosis
--------------------------------------

It is necessary for multicellular organisms to keep a balance between proliferation and apoptotic cell death. If this well controlled balance is disrupted, the development of cancer may be triggered ([@B21]). Induction of apoptosis has become an effective strategy for cancer prevention and treatment ([@B57]; [@B31]; [@B35]). However, if the apoptosis is suppressed in tumor cells, these cells will survive and even resist chemotherapy. Studies have shown that the treatment with various forms of H~2~S donors could induce cell apoptosis in cancer. For example, the exposure of oral cancer cells to H~2~S gas for 72 h markedly led to apoptotic cell death, but did not affect healthy oral keratinocytes ([@B72]). It was found that the expression of CSE in human melanoma cells was elevated and the overexpressed CSE provoked spontaneous apoptosis. Importantly, exogenously applied H~2~S donor, DATS, or CSE substrate, [L]{.smallcaps}-cysteine, can both inhibit tumor growth in mice ([@B77]). In addition, the slow-releasing donor GYY4137 could trigger apoptosis of many types of cancer cells, including HeLa, HCT-116, Hep G2, HL-60, MCF-7, MV4-11, and U2OS, causing significant inhibition of tumor growth ([@B55]).

On the other hand, several reports showed that H~2~S of GI tract could inhibit the phytochemical agent β-phenethyl isothiocyanate-induced cellular apoptosis in human colon cancer HCT116 cells ([@B82]). Moreover, the application of exogenous H~2~S, in the form of NaHS at concentration of 500 μM, dramatically increased cell viability but decreased the number of apoptotic cells through activation of NF-κB pathway in PLC/PRF/5 hepatoma cells ([@B146]).

From these studies, it can be noticed that the effects of H~2~S on cellular apoptosis are also contradictory, similar to its effects on proliferation. Therefore, more related and designed research has become imperative.

Effects of H~2~S on Angiogenesis
--------------------------------

In cancer progression, including tumor growth, invasion, and metastasis, angiogenesis plays a vital role through supplement of oxygen and nutrients ([@B137]). The proliferation and migration of endothelial cells and fibroblasts are the base for angiogenesis, and this progress is regulated by a number of growth factors, such as VEGF, fibroblast growth factor, and epidermal growth factor ([@B12]; [@B117]). H~2~S, in the form of NaHS, could induce VEGF expression and promote angiogenesis in soluble fms-like tyrosine kinase 1 (sFlt1)-mediated renal injury ([@B40]) or in hind limb ischemic rats ([@B113]). Since VEGF-mediated angiogenesis contributes to cancer progression, H~2~S's pro-angiogenic activity may cause cancer, which is supported by some recent studies. In colon cancer, H~2~S produced by CBS in tumor can stimulate angiogenesis, increase tumor blood flow and ATP generation, resulting in tumor growth. The pharmacological inhibition of H~2~S generation with a selective CSE inhibitor, aminooxyacetic acid, could impede endothelial cell migration and tumor cell proliferation, migration, and invasion ([@B94]; [@B93]). In ovarian cancer, similar H~2~S pro-angiogenic effects on tumor growth were also demonstrated ([@B7]; [@B39]). Besides VEGF induction, H~2~S can activate its receptor VEGFR2 via breaking Cys1045--Cys1024 disulfide bond ([@B99]). Despite the aforementioned anti-proliferation and pro-apoptosis, H~2~S may be used in cancer therapy. However, its proangiogenesis will impede the use in this field. In combination of VEGF neutralizing antibody or VEGFR2 antagonist may overcome this effect of H~2~S on angiogenesis and contribute to its anti-cancer effects.

Hydrogen Sulfide and Glycometabolism Disorder
=============================================

Diabetes mellitus (DM) is another common issue affecting public health. As reported by WHO, the number of patients suffering DM has exceeded 420 million throughout the world. It is noteworthy that diabetic patients can carry carcinoma more easily than healthy people ([@B5]; [@B44]; [@B123]; [@B103]). Disorders of glucose metabolism are one of the most important features of DM. A growing body of evidence has shown H~2~S plays an important role in the disordered glucose metabolism ([@B110]; [@B104]). In this section, the effects of H~2~S on glucose metabolism are discussed.

Effects of H~2~S on Insulin Secretion
-------------------------------------

In the human body, there are many hormones which can increase blood glucose, such as growth hormone, glucocorticoid, and glucagon. However, insulin is the only hormone that decreases blood glucose. Consequently, insulin's abnormal secretion or/and dysfunction is the significant reason for glycometabolism disorder. In general, H~2~S can affect insulin-secreting beta cells in two ways, i.e., inhibiting secretion of insulin from the cells ([@B133]; [@B95]), and preventing them against various stimuli-induced cellular apoptosis ([@B61]; [@B74]).

It is documented that in streptozotocin (STZ)-induced diabetic rats, the expression of H~2~S synthetases, including CSE and CBS, in the liver and pancreas is significantly upregulated comparing with the control rats. The induction of the two enzymes is restored by the exogenous supplement of insulin ([@B135]). In an *in vitro* study, the administration of H~2~S to INS-1E cells, a beta cell line, obviously attenuates insulin secretion triggered by a high concentration of glucose ([@B133]). In another beta cell line, HIT-T15 cells, similar findings have been demonstrated. In addition, it is reported that the inhibitory effects of H~2~S on insulin secretion depend on opening K~ATP~ channels ([@B1]). These studies indicate that under diabetic conditions, the elevated levels of endogenous H~2~S can open K~ATP~ channels in islet beta cell membrane, resulting in hyperpolarization of membrane potential and reduction of insulin secretion ([@B133]). Besides working as a K~ATP~ channel opener, H~2~S provided by NaHS can directly inhibit L-type voltage-dependent Ca^2+^ channels, thereby reducing insulin secretion in a K~ATP~ channel-independent manner ([@B95]). In MIN6 cells, a pancreatic beta cell line, through decreasing the intracellular ATP content, the enhancement of H~2~S generation by [L]{.smallcaps}-cysteine can also indirectly open K~ATP~ channels and then inhibit insulin secretion ([@B48]). All of these studies manifest that H~2~S inhibits insulin secretion by targeting various links, including inhibition of ATP synthesis, activation of K~ATP~ channels and inactivation of L-type voltage-dependent Ca^2+^ channels, respectively ([@B110]; **Figure [11](#F11){ref-type="fig"}**).

![Effects of H~2~S on insulin secretion by beta cells. **(A)** Insulin secretion is stimulated at high glucose levels and **(B)** inhibited at high H~2~S or low glucose levels. GLUT2, glucose transporter type 2; G, glucose; G-6-P, glucose 6-phosphate; MITO, mitochondria; ○, targets of H~2~S; ⊕, to activate; Θ, to inhibit.](fphar-08-00664-g011){#F11}

Similar to STZ-induced diabetic model, Zucker DM rats have higher endogenous H~2~S content than obese rats. Notably, the inhibition of endogenous H~2~S synthesis in Zucker DM rats improves insulin release and relieves hyperglycemia ([@B121]). These studies demonstrate that H~2~S can inhibit insulin secretion, and the downregulation of H~2~S system seemingly benefits diabetic prevention and treatment.

Actually, endogenous H~2~S does not always work as a foe. For example, some researchers have shown that H~2~S can prevent islet beta cells from various stimuli-induced injury ([@B47]; [@B98]). CBS is widely expressed in the whole pancreas, while CSE is mainly expressed in the islets of pancreas. In the isolated pancreatic beta cells, basal CSE expression is very low, but can be elevated by the treatment with high concentrations of glucose. Additionally, both exogenous administration of H~2~S (NaHS) and stimulating endogenous H~2~S generation with [L]{.smallcaps}-cysteine can impede oxidation-induced cellular apoptosis ([@B47]). Besides excessive apoptotic death of beta cells, the persistently elevated inflammatory response can damage islet cells and cause many diabetic complications. Therefore, DM has been accepted as an inflammatory response disease and thus anti-inflammation is a very important way to treat DM ([@B24], [@B25]; [@B28]). Interestingly, the application of NaHS to release H~2~S can significantly inhibit proinflammatory factors-induced injury in primary cultured pancreatic beta cells and MIN6 cells ([@B97]). In HFD-induced type 2 DM mice, the knockout of CSE (to reduce H~2~S) aggravates oxidation-related insults without promotion of insulin secretion or reduction of blood glucose levels ([@B74]). Our studies indicate that in diabetic skin complications, H~2~S provided by NAC or NSHD-1, a synthetic slow-releasing H~2~S donor, can exert protective effects against diabetes-like injury ([@B129], [@B128]). However, some other studies have shown that H~2~S participates in ER stress-mediated cellular apoptosis through activation of p38 MAPK pathway ([@B131]), which is not completely consistent with the report by [@B97].

Based on the above studies, it can be summarized that the effects of H~2~S on insulin secretion vary and may be dependent on different stages of diabetic development. At the early stage, hyperglycemia-induced CSE upregulation may be a protective mechanism in the body. The increased H~2~S level can exert anti-oxidation, anti-inflammation, and inhibition of autoimmune response, consequently protecting pancreatic beta cells. With the diabetic development, the content of H~2~S further increases, and the elevated H~2~S will inhibit insulin secretion and then reduce the overload of diabetic beta cells via reduction of ATP content, activation of K~ATP~ channels, or inhibition of L-type voltage-dependent calcium channels ([@B73]). However, if the hyperglycemia state persists, the endogenous content of H~2~S will exceed its threshold, which triggers ER stress response and resultant apoptosis ([@B131]). Therefore, the regulation of endogenous H~2~S generation is very important, i.e., at the early stage of DM, the administration of H~2~S may be beneficial, while at its late stage inhibiting H~2~S generation may be a reasonable treatment strategy.

Effects of H~2~S on Hepatic Glucose Metabolism
----------------------------------------------

The liver is an important organ to control blood glucose homeostasis, by balancing glycogen synthesis, to reduce blood glucose levels, and gluconeogenesis, to raise blood glucose levels. Hepatic malfunction can also lead to abnormal glucose metabolism, even diabetic development. Importantly, H~2~S plays a potential role in the glucose metabolism in the liver. In HepG2 hepatocytes, H~2~S (NaHS) can inhibit glucose uptake and glycogen storage through reduction of glucokinase activity ([@B141]). Additionally, NaHS can induce gluconeogenesis and glycogen breakdown via phosphoenolpyruvate carboxykinase in liver ([@B105]). By these means, H~2~S can increase blood glucose levels. However, it was also found that under physiological conditions, the effects on CSE/H~2~S signal was inhibited by insulin, and perhaps H~2~S does not significantly regulate hepatic glucose output ([@B141]). When hyperglycemia persists or insulin resistance develops, the CSE/H~2~S signal is obviously activated. A further study showed that the elevated H~2~S content can cause pyruvate carboxylase *S*-sulfhydration and activation, increasing gluconeogenesis and blood glucose levels. Interestingly, the expression of CSE can be increased by glucose deprivation, but decreased by a HFD, indicating that hepatic H~2~S generation is significant to maintain glycemic homeostasis ([@B45]).

Effects of H~2~S on Glucose Metabolism of Adipose Tissues
---------------------------------------------------------

When blood glucose increases, the adipose tissues can store the excessive glucose as body fat. Conversely, when blood glucose decreases, some fat stored in adipose tissues can be mobilized and used for gluconeogenesis and energy. Therefore, the adipose tissues usually serve as another buffer for blood glucose in the body alongside the liver. It was found that CSE is expressed in adipose cells and preadipocytes. Stimulating endogenous H~2~S production with [L]{.smallcaps}-cysteine can inhibit glucose uptake by adipose tissues via reducing insulin sensitivity ([@B30]). A 2-deoxy-\[(3)H\] glucose uptake experiment *in vivo* showed that the basal and insulin-stimulated glucose uptake by adipose tissues of Kir 6.2(-/-) mice, deficient in the function of K~ATP~ channel, is enhanced compared with that of wild-type mice ([@B71]), which is supported by an earlier study ([@B100]). As a K~ATP~ agonist, it is reasonable that H~2~S has an opposite effect comparing with the knockout of Kir 6.2. However, [@B30] study showed that the effects of H~2~S do not depend on K~ATP~ channels, but are rather associated with PI3K signaling pathway. Besides inhibition of glucose uptake, H~2~S is involved in TNFα-induced insulin resistance in 3T3-L1 adipocytes ([@B42]). Therefore, for the regulation of glucose uptake by adipose tissues H~2~S does not seem to play a beneficial role.

It is worthwhile to note that some recent studies showed the opposite action of H~2~S on glucose regulation by adipose tissues. [@B68], [@B69]) found that the administration of H~2~S (Na~2~S) or its stimulating agent ([L]{.smallcaps}-cysteine), even VD, can enhance the ability of adipose tissues to take up glucose. This effect is associated with increases in insulin sensitivity and GLUT4 activity. In another *in vivo* study, H~2~S (NaHS) was found to promote adipocytes to uptake glucose and thus reduce fasting blood glucose levels and increase glucose tolerance ([@B124]). Besides the improvement of adipocyte function, H~2~S can protect the adipocytes against high concentration of glucose-induced adipocyte dysfunction, evidenced by the restored monocyte chemotactic protein (MCP)-1 and adiponectin secretion ([@B76]). In addition, H~2~S can modulate adipogenesis and adipocyte maturation ([@B102]). Hence, the roles of H~2~S in glucose homeostasis regulated by adipose tissues are very complicated and even contradictory. The reason for this may be related to the amount of H~2~S, processing time, experimental model, and diabetic development stage.

Future Directions
=================

To Develop More Selective CSE/CBS Modulator
-------------------------------------------

In recent years, H~2~S has received much increased attentions in biomedical fields because of its functions in physiological and pathophysiological processes. As discussed above, endogenous H~2~S not only plays many beneficial roles, but also exerts a great number of adverse effects in the body. Thereby, its fine modulation may have great therapeutic significance for some diseases. Genetic approaches are very useful for basal studies in animals or cells, by modulating the deficiency or overexpression of CSE/CBS. However, in clinical trials, pharmacological approaches should be more promising by modulating CSE/CBS expression or activity with a selective agonist/antagonist ([@B109]), which is still quite scarce although there are a handful of non-selective ones. Searching for more selective inhibitors or stimulators of CSE/CBS should be attractive for researchers.

To Develop H~2~S Donor Materials with Targeted Delivery
-------------------------------------------------------

Another pharmacological approach is what we have mainly focused on in the present article, i.e., H~2~S releasing agents. Studies in this field have made fantastic progress, especially in recent years. Through this article, we can see that present donors have gradually been improved in water-solubility, stability, releasing controllability, and byproduct toxicity. Nevertheless, one should bear in mind that targeted delivery is critically affecting clinical usage. For example, some compounds have rather unique effects in cellular experiments or local administration in animals, while no effects were found when used systemically. Additionally, it is local rather than systemic H~2~S changes that lead to the pathology or disease. Consequently, a rise in local H~2~S content will be more valuable in *ex vivo* application of H~2~S. In this regard, ROS-activated ([@B144]) and pH-controlled H~2~S donors ([@B49]) may partially possess this feature. Targeted delivery of H~2~S donors or materials should be another exciting research topic.

Conclusion
==========

H~2~S has been considered as one of the endogenous gaseous signaling molecules with various effects in the body. In some pathological process, e.g., cancer and glycometabolic malfunction, different studies show that H~2~S may exert different or even opposite actions. The reasons may be complex or even perplexing; thereby more related studies are still required to reveal the mystery. Nevertheless, reduced endogenous H~2~S has been linked to the cause of many diseases or their stage-dependent injury. Therefore, to enhance endogenous H~2~S content is of great pharmacological significance with the use of H~2~S releasing/stimulating reagents. It is gratifying to see the development of H~2~S releasing reagents has made great progress in recent years. It is anticipated that this will continue to be an active research topic. We expect to see more interesting work arising in this field.
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